Market Overview

Biomarkers Markets 2017-2027: Proteomics, Metabolomics, Molecular Diagnostics, Drug Discovery, Clinical Trials, and Bioinformatics -


The "Biomarkers
- Technologies, Markets and Companies"
report from Jain
PharmaBiotech has been added to's

This report follows the broad definition of a biomarker as a
characteristic that can be objectively measured and evaluated as an
indicator of normal biological or pathogenic processes as well as
pharmacological responses to a therapeutic intervention. Tests based on
biomarkers have been around for more than half a century, but interest
in their application for diagnostics and drug discovery as well as
development has increased remarkably since the beginning of the 21st

This report describes different types of biomarkers and their discovery
using various -omics technologies such as proteomics and metabolomics.
Molecular diagnostics technologies are used for the discovery of
biomarkers and new tests are also based on biomarker.

Currently the most important applications of biomarkers are in drug
discovery and development. The role of biomarkers in various therapeutic
areas particularly cancer, cardiovascular diseases and disorders of the
central nervous system, is described. Biomarkers are useful not only for
diagnosis of some of these diseases but also for understanding the
pathomechanism as well as a basis for development of therapeutics.

Biomarkers will facilitate the combination of therapeutics with
diagnostics and will thus play an important role in the development of
personalized medicine. Biomarkers play a role in use of
pharmacogenetics, pharmacogenomics and pharmacoproteomics for
development of personalized medicine.

Many of the regulatory issues concerning biomarkers are related to
genomics, proteomics, molecular diagnostics and
pharmacogenomics/pharmacogenetics. Validation of biomarkers and their
role in clinical trials is discussed.

Biomarker markets are estimated from 2017 to 2027 according to share of
markets for various technologies and applications: proteomics,
metabolomics, molecular diagnostics, drug discovery, clinical trials,
and bioinformatics. Market values are further split according to
therapeutic applications and major geographical areas. Unfulfilled needs
in biomarkers are identified as well as the drivers for biomarker
markets. Challenges facing the biomarker industry and strategies for
developing biomarker markets are discussed.

A large number of companies with varying technical backgrounds are
involved in biomarkers and 299 of these are profiled in part 2 of the
report with classification into various categories. These also include
major pharmaceutical companies. There is tabulation of 465
collaborations between companies and additional academic collaborations
are mentioned in the individual profiles of companies. The report is
supplemented by 1000 references, 81 tables and 23 figures.

Key Topics Covered:

Part 1: Technologies & Applications

Executive Summary

1. Introduction

2. Technologies for Discovery of Biomarkers

3. Biomarkers and Molecular Diagnostics

4. Biomarkers for Drug Discovery & Development

5. Role of Biomarkers in Healthcare

6. Biomarkers in Metabolic Disorders

7. Biomarkers in Immune Disorders

8. Biomarkers of Musculoskeletal Disorders

9. Biomarkers of Infectious Diseases

10. Biomarkers of Genetic Disorders

11. Biomarkers of Aging

12. Nutritional Biomarkers

13. Biomarkers of Cancer

14. Biomarkers of Disorders of the Nervous System

15. Biomarkers of Cardiovascular Disorders

16. Biomarkers of Pulmonary Diseases

17. Biomarkers in Gynecology and Obstetrics

18. Biomarkers & Personalized Medicine

19. Biomarkers and Regulatory issues

20. References

Part II: Markets & Companies

21. Markets for Biomarkers

22. Companies

For more information about this report visit

View Comments and Join the Discussion!